Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

March 19, 2025 at 17:00 PM EDT

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that multiple abstracts will be presented at the 40^th Annual European Association of Urology Congress (EAU25) demonstrating the clinical performance and utility of its Decipher tests in prostate and bladder cancer. Additionally, independent performance data supporting the company’s minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer will be unveiled from a large, multicenter trial. The EAU25 meeting is taking place March 21-24 at IFEMA Madrid in Spain.

“These new data reinforce the impact our Decipher tests are having on patient care in prostate and bladder cancers and how our whole-transcriptome approach is enabling us to partner with researchers to fuel new insights into the underlying biology of these diseases,” said Philip Febbo, M.D., Veracyte’s chief scientific officer and chief medical officer. “We are similarly deploying a whole-genome approach with our MRD testing platform and are excited to see data from the TOMBOLA trial at EAU25 that reinforce the strong performance of our MRD platform for muscle-invasive bladder cancer. We plan to launch a test for this indication next year.”

The following Decipher- and MRD-focused abstracts will be presented at EAU25:

PROSTATE CANCER:

Title:		Transcriptomic profiling of the tumor immune microenvironment reveals prognostic markers in mCRPC patients treated with LuPSMA therapy
Presenter:		Analena Handke, M.D., Ruhr University Bochum, Bochum, Germany
Format:		Poster (#P195)
Date/Time:		Saturday, March 22, 11:30-12:00 CET
Location:		Green Area, EGPT 2

Title:		Transcriptomic expression patterns in very high risk Decipher >0.85
Presenter:		Nicole Handa, M.D., Northwestern University, Chicago, Ill.
Format:		Oral (#A0587)
Date/Time:		Sunday, March 23, 15:30-16:10 CET
Location:		Purple Area, Room 1

BLADDER CANCER:

Title:		Discrepancy between clinical and pathological stage after radical cystectomy: Results from a nation-wide prospective cohort study
Presenter:		Joep J. de Jong, M.D., Erasmus University Medical Center, Rotterdam, The Netherlands
Format:		Oral (#A0122)
Date/Time:		Friday, March 21, 16:15-16:40 CET
Location:		Pink Area, N103

Title:		A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer
Presenter:		Joep J. de Jong, M.D., Erasmus University Medical Center, Rotterdam, The Netherlands
Format:		Oral (#A0504)
Date/Time:		Sunday, March 23, 14:35-15:15 CET
Location:		Pink Area, N101

Title:		Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like genomic profile with favorable prognosis after neoadjuvant chemo and immunotherapy
Presenter:		Joep J. de Jong, M.D., Erasmus University Medical Center, Rotterdam, The Netherlands
Format:		Oral (#A0508)
Date/Time:		Sunday, March 23, 14:35-15:15 CET
Location:		Pink Area, N101

Title:		Gene expression signatures of immune infiltration portend differential response to sequential Intravesical Gemcitabine and Docetaxel versus Bacillus Calmette-Guerin in High-Risk Non-Muscle-Invasive Bladder Cancer
Presenter:		Joep J. de Jong, M.D., Erasmus University Medical Center, Rotterdam, The Netherlands
Format:		Oral (#A0674)
Date/Time:		Sunday, March 23, 17:15-17:50 CET
Location:		Pink Area, N101

Title:		The Estrogen Response Pathway as a Putative Predictive Biomarker of Neoadjuvant Pembrolizumab benefit in Patients with Muscle-Invasive Bladder Carcinoma (MIBC)
Presenter:		Joep J. de Jong, M.D., Erasmus University Medical Center, Rotterdam, The Netherlands
Format:		Poster (#P598)
Date/Time:		Monday, March 24, 13:10-14:00 CET
Location:		Green Area, EGPT 1

MRD:

Title:		Comparison of ctDNA detection methods for monitoring minimal residual disease in patients with bladder cancer: Insights from the TOMBOLA trial
Presenter:		Iver Nordentoft, Ph.D., Aarhus University, Aarhus, Denmark
Format:		Oral (#A0162)
Date/Time:		Saturday, March 22, 10:32-11:15 CET
Location:		Purple Area, Room 1

About Decipher Prostate

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test's performance and clinical utility has been demonstrated in over 85 studies involving more than 200,000 patients. It is the only gene expression test to achieve “Level IB” evidence status and inclusion in the risk-stratification table in the most recent NCCN® Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.

About Decipher Bladder

The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to how our whole-transcriptome approach is enabling us to partner with researchers to fuel new insights into the underlying biology of these diseases and our plan to launch a test for this indication next year. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to the potential impact the Veracyte Diagnostics Platform can have on scientific advancements in cancer and, in turn, patient care. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2025. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

* National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319933886/en/

Contacts

Investors:

Shayla Gorman

investors@veracyte.com

619-393-1545

Media:

Tracy Morris

media@veracyte.com

650-380-4413

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Contacts

More News